Načítá se...
Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma
The BCL6 oncogene plays a crucial role in sustaining diffuse large B-cell lymphomas (DLBCL) through transcriptional repression of key checkpoint genes. BCL6-targeted therapy kills lymphoma cells by releasing these checkpoints. However BCL6 also directly represses several DLBCL oncogenes such as BCL2...
Uloženo v:
| Vydáno v: | Oncotarget |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Impact Journals LLC
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4823124/ https://ncbi.nlm.nih.gov/pubmed/26657288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6513 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|